JY
CSTL icon

Jeff Yass’s Castle Biosciences CSTL Stock Holding History

Jeff Yass’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,500
Closed -$253K – 12605
2024
Q4 		$253K Buy
9,500
+100
+1% +$3.05K ﹤0.01% 10189
2024
Q3 		$268K Buy
+9,400
New +$239K ﹤0.01% 9827
2023
Q4 		– Sell
-18,600
Closed -$314K – 12475
2023
Q3 		$314K Sell
18,600
-16,200
-47% -$283K ﹤0.01% 9245
2023
Q2 		$477K Buy
+34,800
New +$705K ﹤0.01% 8427
2022
Q1 		– Sell
-5,000
Closed -$214K – 13109
2021
Q4 		$214K Sell
5,000
-5,900
-54% -$308K ﹤0.01% 11302
2021
Q3 		$725K Sell
10,900
-13,200
-55% -$929K ﹤0.01% 8413
2021
Q2 		$1.77M Buy
24,100
+8,100
+51% +$535K ﹤0.01% 6203
2021
Q1 		$1.09M Sell
16,000
-1,700
-10% -$128K ﹤0.01% 7495
2020
Q4 		$1.19M Buy
17,700
+10,000
+130% +$542K ﹤0.01% 6313
2020
Q3 		$396K Buy
7,700
+700
+10% +$31.1K ﹤0.01% 8152
2020
Q2 		$264K Buy
+7,000
New +$239K ﹤0.01% 8577

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jeff Yass's CSTL Position: Q2 2026 in Review

Jeff Yass sold out of Castle Biosciences (CSTL) in Q2 2026, closing a stake of 9,520 shares — an estimated $234K sold.

Jeff Yass first reported a position in CSTL in Q2 2020 and held it in 14 quarters. The position peaked at $3.04M in Q1 2021. 175 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Jeff Yass reported no remaining Castle Biosciences position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 9,520 Castle Biosciences shares in Q2 2026, an estimated $234K.
  • Jeff Yass first reported a position in Castle Biosciences in Q2 2020 and held it in 14 quarters.
  • Jeff Yass's Castle Biosciences position peaked at $3.04M in Q1 2021.
  • 175 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.